CN Patent

CN104739835A — 一种治疗糖尿病的新型药物组合物

Assigned to Waterstone Pharmaceuticals Wuhan Co Ltd · Expires 2015-07-01 · 11y expired

What this patent protects

本发明属于医药技术领域，涉及一种治疗糖尿病的新型药物组合物，是以阿格列汀和卡格列净为活性成分，配以药学上可接受的药用载体。本发明的药物组合物具有高效协同作用，方便病人给药，能够更加有效的治疗糖尿病。

USPTO Abstract

本发明属于医药技术领域，涉及一种治疗糖尿病的新型药物组合物，是以阿格列汀和卡格列净为活性成分，配以药学上可接受的药用载体。本发明的药物组合物具有高效协同作用，方便病人给药，能够更加有效的治疗糖尿病。

Drugs covered by this patent

Patent Metadata

Patent number
CN104739835A
Jurisdiction
CN
Classification
—
Expires
2015-07-01
Drug substance claim
No
Drug product claim
No
Assignee
Waterstone Pharmaceuticals Wuhan Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.